ABSTRACT
The VesiVax  system is based upon the concept that highly potent vaccines can be designed by engineering proteins that are capable of stably inserting themselves into liposomes. Such a nanoscale liposomal particle can then serve as an immunogen for vaccine development. The VesiVax  vaccine technology platform is designed to make it relatively easy to engineer and produce new vaccines quickly. Vaccines based on the VesiVax  system have been designed against the influenza virus and herpes simplex type 2 virus, the causative agents of the "flu" and genital herpes, respectively. Both vaccines have been tested in animal models and have demonstrated significant protective efficacy from challenge with lethal doses of virus. Assays of the immunological parameters suggest that both T and B cell responses can be elicited by VesiVax  vaccines. The safety profile of the VesiVax  vaccines is expected to be much better than that of vaccines prepared by conventional techniques. Taken together, the inherent flexibility of the VesiVax platform is expected to facilitate the rapid development of new vaccines which are effective at stimulating protective immune responses.
INTRODUCTION
Immunization against biological agents has a long history of being a safe and effective method of protecting large populations against infectious diseases. The most successful of these vaccines have been based on immunization with the intact pathogen. Since many of the most important human pathogens exhibit minimal antigenic variation, little emphasis has been placed on flexibility to respond quickly to new, rapidly emerging pathogens. However, the possibility of the appearance of a highly virulent pathogen either through a natural outbreak or the deliberate release of an engineered microbe has exposed the underlying weaknesses associated with the classical methods of vaccine development and production that rely primarily on the use of the pathogen itself or a similar agent as the immunogen.
For example, development of microbial-based vaccines generally requires a lengthy period of time and often results in a unique set of production conditions that are not broadly applicable to other pathogens, which makes it difficult to streamline the vaccine development process (1). Classical vaccines may also suffer from a number of additional problems including low efficacy, severe adverse side effects and protective immunity of limited duration. Thus, although vaccination is regarded as one of the greatest achievements in medicine, improvements in the form of new vaccine technologies are greatly needed.
While generally safe, vaccines that employ intact organisms can be associated with serious toxic reactions. For instance, the smallpox vaccine is based on a strain of vaccinia virus that has a very well documented history of causing significant morbidity and mortality (2). Occasionally, immunization can precipitate the development of autoimmune diseases directed against normal tissues (e.g., Guillain-Barre' syndrome) (3) . In addition to the agents themselves, vaccine production within cells or complex artificial media may allow for the induction of severe allergic reactions to foreign proteins incorporated in the vaccine preparation (4) . Bacterial vaccines can also have undesirable side effects: certain pertussis vaccines cause some very severe complications in children (e.g., vomiting, anorexia, convulsions, pain, fever) because of endotoxins present in the vaccine (5) while the widely used BCG vaccine for tuberculosis has been shown to cause a number of adverse reactions, including local abscesses at the site of injection, lymphadenitis, pulmonary lesions and even bone lesions (6) . Since effective vaccination procedures frequently require multiple immunizations, these adverse events can seriously compromise the effectiveness of the vaccine and may reduce public acceptance of the vaccination procedure.
Modern molecular biologic techniques promise to provide increased safety and efficacy for non-pathogen based vaccine technologies. Some of the more popular strategies for immunization that have been under investigation include: vaccines based upon recombinant proteins (7,8), generation of simple synthetic peptides as antigens (9) (10) (11) (12) and the direct injection of genetic material into tissues to stimulate protective immune responses (13) (14) (15) . In particular, the use of protein or peptide antigens to induce specific immune responses has been the focus of many studies. This strategy is attractive because it has the potential to provide immunological specificity, tighter control of manufacturing processes, and elimination of most of the secondary sources of materials or contaminants associated with the production of the immunogen.
The use of purified proteins or peptide fragments for vaccination, however, depends upon the delivery of the antigens to the immune system by an effective carrier system.
Protein and peptide antigens are typically ineffective in stimulating host immune responses when used as soluble antigens. Zinkernagel and colleagues have proposed that the important variables that determine the effectiveness of an immune response are antigen localization and concentration (16) , conditions that are difficult to achieve with small soluble molecules. Immune responses require both exposure to the appropriate responding cells and sufficient antigen to stimulate an effective response. Soluble antigens can, however, be manipulated to more effectively stimulate immune responses, either by incorporation into a carrier system that distributes the antigen more efficiently to the cells of the immune system, thereby facilitating better uptake by antigen presenting cells (APC), or by attracting more APC to the site of antigen localization (17) . Alternatively, carriers that release soluble antigen over time can enhance the response by extending exposure of immune cells to antigen. The choice of a carrier system that effectively promotes antigen presentation is nearly as important as selecting the target antigen for vaccine development.
One potential method to improve the immunogenicity of soluble antigens is to incorporate them into a carrier system such as a liposome. The ability of liposome/antigen complexes to efficiently stimulate the cells of the immune system (e.g., macrophages) can be a highly effective delivery system for well-defined protein epitopes.
Small unilamellar liposomes (<200nm) administered in vivo can circulate widely throughout the body and their particulate structure stimulates removal by the monocyte/macrophage phagocytic system, especially in the liver, spleen, lymph nodes, and lungs (18) (19) (20) . Vaccination studies using these constructs have shown that lipid and liposome-based antigen complexes promise to be safe and effective carriers for a variety of vaccine applications (21) (22) (23) (24) (25) (26) (27) (28) . However, while formulations based on these strategies have been shown to be immunologically active, technical difficulties associated with the large-scale production of proteins with lipophilic domains that allow for efficient interaction with liposomes have made them less attractive for commercial vaccine applications. Clearly, an improved system or method for incorporating protein antigens in a liposome is required to take advantage of the potential offered by liposomes in vaccine development.
THE VESIVAX  SYSTEM
One recently developed strategy for addressing the problems associated with liposomal delivery of antigens has been to design and engineer proteins that are capable of being stably inserted into lipid bilayers. This approach requires a fundamental understanding of the interactions of proteins and/or peptides with lipid bilayers and an in-depth knowledge of the processes used in the commercial preparation of liposomes (29) . Structural and functional studies on the interactions of proteins and peptides with lipid bilayers has, for instance, identified structural amphiphilicity and hydrophobicity as important parameters that control the nature of the interaction between proteins and membranes (30) (31) (32) . By taking advantage of this information, the VesiVax  vaccine system was created which, in the most optimal version, employs a flexible and easily modified gene cassette designed to rapidly engineer and produce antigenic proteins that are compatible with liposomal bilayer membranes. These specially-engineered proteins possess an aqueous soluble hydrophobic domain (HD) that makes purification simple and allows stable insertion of the immunogen within the lipid membrane for use as a vaccine. The VesiVax  system has been extensively tested and shown to be highly effective for immunizing against several different bacterial and viral infections. This technology eliminates one of the most critical issues associated with hydrophobic protein domains that make large-scale vaccine development difficult, i.e., the production and purification of proteins with hydrophobic regions using standard preparative techniques.
Several prototypic VesiVax  vaccines have been constructed, evaluated and demonstrated to provide protection against a number of different pathogens. The procedures for preparing each antigen protein and formulating the liposomes are essentially the same for each vaccine. As described here, epitopes from the N-terminus of the gD envelope protein of herpes simplex virus type 2 (HSV2) and the M2 ectodomain (M2e) from influenza virus type A (IAV) were prepared as fusion proteins coupled to an HD segment and purified. It has been demonstrated in experimental animal (HSV2; IAV) models that the vaccines incorporating the HSV2 and IAV HD constructs provide protection against challenge with viral pathogens administered by several different routes of infection (e.g., respiratory, vaginal, rectal) with no evidence of vaccine-related adverse side effects (33, 34) . VesiVax  vaccines are highly immunogenic, stimulating protective immune responses in both male and female as well as in adult and young animals. Because the VesiVax system is designed to be flexible, antigens ranging from epitope segments as small as 10-15 amino acids to larger proteins of several hundred amino acids can easily be accommodated. Taken together, the results suggest that the application of modern molecular biologic techniques to quickly identify new antigenic determinants from emerging pathogens in combination with an antigen/lipid carrier designed to stimulate potent protective immune responses could potentially facilitate the rapid development of new vaccines.
CONSTRUCTION OF A VESIVAX  VACCINE
The construction of a VesiVax  vaccine begins with the identification of an appropriate target antigen or epitope. Examples of promising target antigens include the M2e protein from IAV and the gD envelope protein from HSV2. The M2 antigen has been proposed as a potential "universal" antigen to induce protection against a broad range of influenza viral subtypes since Zebedee and Lamb first raised a monoclonal antibody (14C2) to the Nterminus of M2 that restricted viral growth (35) and was subsequently shown in passive transfer experiments to inhibit viral replication in mice (36) . A recombinant M2 protein expressed in baculovirus stimulated antibodies to M2 (37) and provided protection as an immunogen in mice against both homologous and heterologous influenza challenge (38) . Others have expressed fusion proteins containing segments of M2 coupled to the Hepatitis B core protein (HBc) (39) or deletion mutants (40) and elicited protective responses to both homologous and heterologous challenge with IAV. The gD envelope protein of HSV has been the focus of many vaccine studies because immunization using gD from either HSV1 or HSV2 viruses protects animals from viral challenge (41) (42) (43) (44) (45) and has been shown to be an important target of the host humoral and cellular immune responses (46, 47) . Studies with monoclonal antibodies specific for gD indicate that this protein plays a role in recognition and binding (48, 49) , penetration (48) and cell fusion (50) of the virus. Within the gD protein, a number of epitopes have emerged as potential targets for vaccine development. Amino acids 1 to 23 of the mature form of gD (gD23) stimulate both humoral (51) and cell-mediated responses (52-54) and mice immunized with synthetic peptides within this region are protected from lethal or paralytic viral challenge (52) . In this review, VesiVax  vaccines based on M2e and gD23 will be discussed.
Once a target antigen has been selected, a VesiVax  vaccine can be prepared either by peptide synthesis or by recombinant methods. While peptide synthesis is relatively straightforward, it is limited to smaller antigen or epitope segments. In addition, the requirement of a hydrophobic domain segment makes purification extremely difficult. Thus, a recombinant approach has recently been developed. In this method, a gene encoding the selected antigen is then prepared by directly cloning it from the pathogen of interest or by chemical synthetic methods. With the recent development of techniques for chemically synthesizing larger genes, it is becoming much more convenient to use this method, since the synthesized gene can be codon optimized for the recombinant expression system (e.g., E. coli) to be used. Once the gene encoding the antigen has been obtained, it is then inserted into a plasmid that has been engineered with the appropriate restriction sites adjacent to sequences for the HD gene (AG-HD). The construct is then transformed into E. coli. The resulting AG-HD construct is expressed and the aqueous soluble AG-HD protein is purified using standard affinity and ion exchange column chromatographic methods. As an example, shown in Figure 1 is a SDS-PAGE analysis of several purified M2e-HD constructs that correspond to different strains of influenza. Each was expressed and purified following the same procedure. The technique has been designed to be compatible with large scale manufacturing process technology, which is an important consideration for commercial production of the AG-HD proteins.
Liposome formulation studies were conducted to establish the most immunogenic composition to carry the AG-HD proteins (L-AG-HD). A broad range of lipid combinations were evaluated as mixtures of phosphatidylcholines (PC), cholesterol (CH), phosphatidylglycerols (PG) and adjuvants (e.g., monophosphoryl lipid A (MPL)). Upon processing, as previously described (34) , each liposome preparation is required to meet certain physicochemical parameters in order to advance to immunological screening in animals. This ensures that any formulation selected for clinical development will be capable of being manufactured in commercial quantities. As part of the primary selection criteria, the liposome preparation must form small unilamellar vesicles that remain stable (i.e., no aggregation or precipitation) for an extended period of time. Formulations meeting these specifications were typically found to have mean diameters of approximately 100nm as judged by dynamic light scattering (Figure 2 ). The size distribution and unilamellarity of the liposomes has also been confirmed by electron microscopic analysis (Figure 3 ) (34).
Liposome formulations meeting the above physicochemical criteria were then screened in mice for their ability to stimulate a strong immune response. For example, the M2e segment from influenza virus type A was prepared and groups of BALB/c mice were immunized using different routes of administration (subcutaneously and intranasally), with or without MPL adjuvant, and with different combinations of the liposomes, M2e-HD and adjuvant. Serum was collected one week after the last vaccination and M2e specific antibody titers measured. The results (Figure 4 ) (34) show that the liposomal form of the M2e-HD protein with MPL (L-M2e-HD) elicited the highest immune response as judged by elevation in antibody titers. It was also found, in general, that M2e liposomes containing MPL performed much better than liposomes without the MPL. These results demonstrated the overall validity of the VesiVax  system as a potentially useful vaccine technology that could be used as a platform for rapid vaccine development.
VESIVAX  VACCINES ELICIT PROTECTIVE IMMUNE RESPONSES
Having identified L-AG-HD formulations that stimulate potent immune responses, several studies were conducted in animal challenge models (55) . In an influenza protection study, groups of mice were given a subcutaneous (s.c.) priming vaccination on day 0 followed by an intranasal (i.n.) booster at week 8 with 10-15µg of L-M2e-HD. The vaccinated animals were challenged intranasally with 25, 50 or 150 LD 50 of the X-88 strain of influenza virus. X-88 is an H6N2, recombined viral strain (HA-A/Turkey/Massachusettes/3740/76 x NA-A/Aichi/6/68 and all other genes from A/PR8/34) and contains the M2e target sequence used in the vaccine (55) . To increase the virulence of the virus in the mouse model, this strain has been adapted in mice by successive passaging through mouse lungs. The mice vaccinated with the L-M2e-HD vaccine were able to withstand exposure to viral challenges of up to 150 LD 50 of the X-88 strain whereas all the mice vaccinated with the liposomes without the peptide (control liposomes) died following viral challenge even at the lowest LD 50 challenge dose ( Figure 5 ). In comparison, mice vaccinated with UV inactivated whole virus showed similar protection to the L-M2e-HD vaccine. In another study aimed at demonstrating cross-protection against different H and N strains of influenza, groups of mice were immunized with the L-M2e-HD and tested at the Centers for Disease Control and Prevention against an H1N1 influenza virus (Strain A/PR/8/34) that has an M2e that is homologous with the X-88 (H6N2) virus. The mice were immunized twice (day 0 s.c. and week 8 i.n.) and challenged approximately 10 days after the boost. Mice immunized with L-M2e-HD showed 100% survival compared to 0% survival for the liposome control group (Figure 6) (34) . The lung viral titers of the immunized and challenged mice were also analyzed and found to be reduced by an average of 2.5 log or over 300-fold compared to the control vaccinated mice.
In vaccination studies conducted on HSV2, the causative agent of genital herpes, similar results were obtained that paralleled the influenza results in terms of protective efficacy. These studies were conducted with a chemically synthesized AG-HD corresponding to the Nterminal 23 amino acid segment from the gD envelope glycoprotein (gD23) of HSV2 fused to the HD (gD23-HD). The vaccine efficacy of liposomal gD23-HD containing MPL, gD23-HD mixed 1:1 with alum, gD23-HD mixed with MPL, gD23-HD without adjuvant and control liposomes (no gD23-HD) containing MPL (25µg/dose) was tested in BALB/c female mice. The animals were subcutaneously vaccinated on day 0, week 4 and week 8 and intravaginally challenged week 9 with 10 LD 50 HSV2. No irritation, reddening or swelling occurred at the vaccine injection sites of the mice, except for minor swelling in the group receiving the alum adjuvanted gD23-HD. Maximum protection (100% survival) was observed with the L-gD23-HD containing MPL group while vaccination of gD23-HD without adjuvant or gD23-HD mixed with alum or MPL produced survival rates of only 18% (Figure 7) . None of the mice given the control liposomes survived beyond day 13. L-gD23-HD with MPL was significantly more protective than any of the other formulations (P<0.005).
Having determined that the L-gD23-HD provided significant protective efficacy, BALB/c female mice were vaccinated with L-gD23-HD to compare the protection generated one week (week 9) and twelve weeks (week 20) post-vaccination. At week 9, L-gD23-HD produced 86% survival following challenge with 10 LD 50 of HSV2, with no survivors in the buffer treated group (P<0.05) ( Figure  8A ). When the viral challenge was delayed until week 20, more than half of the L-gD23-HD vaccinated mice were still protected, with a survival rate of 57% ( Figure 8D ) and none of the buffer treated mice survived the challenge (P<0.05 ). The clinical signs of infection in the BALB/c mice paralleled the survival data with severe symptoms for the control mice at both timepoints (Figures 8 B, C, E, and F). Minimal vaginal and neurological signs were observed for the mice given L-gD23-HD and challenged one week post-vaccination (Figures 8 B, C) . However, when the viral challenge was delayed for 12 weeks post-vaccination, the initial symptoms in the L-gD23-HD immunized mice were more severe than at 1 week post-vaccination, with signs resolving by the end of the observation period (Figures 8 E,  F) . Groups of BALB/c mice (n=7/group) were immunized with three subcutaneous injections of L-gD23-HD (-■-), gD23-HD with MPL (-▲-), gD23-HD with alum (-•-), gD23-HD (-∆-) and control liposomes (-□-) at day 0, week 4 and week 8. All mice were primed with depoprovera on day -7 and day -1 prior to intravaginal challenge.
One week later (week 9) mice were intravaginally challenged with 10 LD 50 HSV2. P<0.005, for L-gD23-HD/MPL compared to other groups (Kaplan Meier Log Rank test).
VESIVAX  VACCINES STIMULATE B AND T CELL RESPONSES
Immunological assays were conducted to determine the nature of the immune response elicited by the L-AG-HD constructs. Antibody titers were measured by ELISA from the serum of mice immunized with the LM2e-HD vaccine and the role of these antibodies in protection were further characterized by passive transfer of serum from immunized mice to naïve mice. For the LgD23-HD vaccine, virus neutralization assays from the serum of immunized mice were performed and this serum was tested for protection of naïve mice against HSV-2 challenge. Evaluation of the cellular immune response for the L-M2e-HD vaccine included an adoptive splenocyte transfer study and analysis of the cytokine profiles was done for both the L-M2e-HD and L-gD23-HD vaccines. The results demonstrated that L-AG-HD vaccines can stimulate both humoral and cellular immune responses.
Humoral responses to the liposomal M2e-HD and gD23-HD vaccines
The M2e antigen has previously been shown to stimulate antibody mediated protective immune responses (56) . High M2e specific antibody titers were reported to be elicited in mice vaccinated with L-M2e-HD as judged by ELISA (34) . To determine if the antibodies generated by the L-M2e-HD vaccine would mediate protection, a passive transfer experiment was conducted in which BALB/c mice were immunized with L-M2e-HD, UV inactivated influenza virus (strain X-88) or control liposomes and the serum collected one week after the last vaccination. Naïve BALB/c mice were given pooled immune serum prior to challenge with influenza virus. Animals receiving sera with titers greater than 13,300 (Table 1) obtained from the mice vaccinated with the L-M2e-HD or UV inactivated influenza virus displayed 100% survival whereas mice given sera from mice vaccinated with control liposomes died ( Figure 9 ). Preliminary antibody isotype data by ELISA indicated that an IgG 1 response was stimulated in the L-M2e-HD vaccinated animals, suggesting that a more humoral Th2 response (rather than cell and antibody Th1 response) was elicited by this vaccine. These results support the hypothesis that anti-M2e antibodies can provide protection against influenza infection.
In a comparable study, neutralizing antibodies in the serum of L-gD23-HD vaccinated mice were titered in a neutralization assay. Female BALB/c mice were vaccinated subcutaneously at weeks 0, 4 and 8, with L-gD23-HD or control liposomes. At one week and 12 weeks postvaccination, blood was collected and the serum assayed for neutralizing antibodies. The neutralizing antibody titer was expressed as the reciprocal of the serum dilution that produced 50% reduction in pfu of Vero cells compared to pfu in wells treated with virus alone. The results (Table 2) showed that one week and twelve weeks after their last subcutaneous vaccination, BALB/c female mice vaccinated with L-gD23-HD produced elevated levels of serum neutralizing antibodies compared to buffer treated controls (BALB/c, p=0.0002 (9wks), 0.0092 (12wks) ).
Cellular responses to the liposomal M2e-HD and gD23-HD vaccines
To assess the role of the cellular response in the protective immunity provided by the liposomal M2e-HD vaccine, an adoptive transfer study was performed by isolating splenocytes from BALB/c mice vaccinated with liposomal M2e-HD or control liposomes. Four days after the last vaccination, splenocytes were harvested from the vaccinated mice and transferred to naïve mice at a dose of at least 5 x10 7 splenocytes per mouse. Four hours posttransfer, the animals were intranasally challenged with 10 LD 50 of influenza virus and the morbidity and mortality followed for 21 days. Naïve mice that received splenocytes from mice vaccinated with the liposomal M2e-HD vaccine started dying 6 days after the influenza challenge, as well as the group of mice that received splenocytes from mice vaccinated with the control liposomes. By day 10 post infection, all the mice from both groups had died ( Figure  10 ). These results are consistent with previous studies (56) indicating that the mechanism of the protective effect of M2 is dependent primarily on an antibody response.
To determine which type of T cell response (Th1 or Th2) was upregulated in the immunized mice following vaccination with the L-gD23-HD vaccine, splenocytes were isolated from L-gD23-HD and control (PBS buffer) vaccinated mice and these cells were incubated with the gD23 epitope. Evaluation of the gD23 specific cytokine response by splenocytes from female BALB/c at one week post-vaccination with L-gD23-HD (Figure 11 ) showed increased levels of IL-2, IL-4 and γ-IFN when compared with splenocytes from buffer treated mice. Notably, γ-IFN levels were more than twice that of the other cytokines. Although the γ-IFN levels remained higher than that of the other cytokines at 12 weeks post-vaccination, the γ-IFN levels were lower than they had been at one week postvaccination ( Figure 11 ). The production of IL-2 and IL-4 by the splenocytes from the liposome vaccinated mice in most cases remained about the same 12 weeks postvaccination. Thus, in contrast to the L-M2e-HD influenza vaccine, the L-gD23-HD vaccine appears to stimulate more of a cellular immune response.
To further study the contribution of the T cell response to the protective effect of the L-gD23-HD vaccine, several mouse strains were selected with different T cell immunological deficiencies, including β-2 microglobulin knockout mice, IL-12 knockout mice and γ-IFN knockout mice. β-2 microglobulin knockout mice are unable to mount a CTL response and IL-12 and γ-IFN knockout mice cannot produce these Th1 cytokines. Since NK cells can also play a role in controlling certain viral infections, the vaccine's efficacy was tested in female Beige mice which are deficient in NK cell activity. Lastly, IL-4 knockout mice were immunized with the L-gD23-HD vaccine to determine if the absence of this Th2 cytokine had any effect on the vaccinated animal's ability to respond to HSV2 challenge.
The immunodeficient mice were vaccinated subcutaneously with the L-gD23-HD vaccine on day 0, week 4 and week 8 or on day 0 and at week 8, and challenged one week post-vaccination with 10 LD 50 HSV2. The results showed that protection was only observed in the IL-4 knockout mice and the Beige mice, which had 67% and 71% survival, respectively ( Figure 12 ). The liposome control vaccinated groups for these two strains were not protected and had severe signs of infection. In contrast, neither the L-gD23-HD nor the liposome control treated, γ-IFN, IL-12 or β-2 microglobulin knockout mice were protected from intravaginal HSV2 challenge ( Figure 13 ). These mice had severe vaginal lesions and neurological signs of infection. These data support the conclusion that the protective immune responses elicited by the liposomal gD epitope vaccine primarily involves Th1 type CD4 cells, as well as CD8 cells, and that NK cells do not contribute significantly to immune control of this infection.
From this data, several important observations can be made. First, the presentation of the target antigens in the liposomal format elicits a strong, protective immune response. Second, L-AG-HD vaccines provide a level of protection at least as good as traditional whole virus vaccines even though the immune response is targeted to one specific antigen. Third, production of protective antigen specific antibodies and T-cell mediated immune responses can be stimulated by the L-AG-HD vaccines. Taken together, the VesiVax  vaccine platform technology facilitates the rapid design and engineering of safe and effective vaccines by eliciting protective immune responses whether they are mediated by B or T cells or a combination of both.
PERSPECTIVE
VesiVax  vaccines represent a breakthrough improvement in liposome-based vaccine technology compared to more traditional liposome approaches for several reasons. First, the pathogen specific antigen(s) or epitope(s) can be chemically synthesized or genetically fused using standard molecular biology methods to a proprietary HD to form a protein that promotes stable association of the epitope with the membrane bilayer structure of the liposome. This novel innovation eliminates the need for covalent conjugation of the antigen to the lipids in the bilayer, a process that is often plagued with problems such as inefficient and unpredictable coupling efficiencies and extra processing steps. Second, adjuvant molecules of various types can be incorporated into the liposomes to direct and further amplify the immune response. Following administration, the nanoscale size of the liposomes which are produced (<200 nm), probably allows them to circulate in the body long enough to enter the lymph nodes and spleen and be taken up by the appropriate macrophages, thereby stimulating an effective systemic immune response rather than the localized, restricted response associated with larger, multilamellar liposomes. In addition, the components of VesiVax  vaccines are derived from nonpathogenic sources and hence, safety concerns are not expected to be an issue. Finally, VesiVax  vaccines are amenable to alternative routes of administration such as intranasal, which may prove to be a more acceptable approach for mass distribution and administration of vaccines to protect the public from a natural outbreak of an emerging pathogen as well as an attack with a biological weapon. is extremely flexible and in principle, as long as a target antigen or epitope is known, a vaccine against a specific pathogen can quickly and easily be generated. The Figure 11 . Cytokine analysis by ELISA. Splenocytes from BALB/c female mice subcutaneously vaccinated on day 0, at weeks 4 and 8 with L-gD23-HD (60µg gD23) or PBS buffer (n=5/group), were collected on wk 9. The spleens from 2 or 3 mice were pooled to give a total of two spleen preparations/treatment group. Each spleen preparation (3x10 6 cells/well) was incubated in triplicate with gD23 (20mg/well) for 3 days and the supernates tested for IL-4, IL-2 and γ-IFN by ELISA.
Figure 12.
Beige and IL-4 knockout mouse study. IL-4 Knockout female mice (n=6/group) were vaccinated subcutaneously with L-gD23-HD (60µg/dose) or control liposomes on day 0 and at week 8. Beige female mice (n=7/group) were vaccinated subcutaneously with L-gD23-HD or buffer day 0, week 4 and week 8. All mice were primed with depoprovera on day -7 and day -1 prior to intravaginal challenge on week 9 with 10 LD 50 HSV2 determined for each strain by infection dose studies in the intravaginal model. Mice were monitored for morbidity for 22 days. Symbol legend: L-gD23-HD IL-4 Knockout group (-■-); LgD23-HD Beige group (-▲-); Beige control group (-∆-) and; IL-4 Knockout control group (-□-).
advantages of VesiVax
 technology for the rapid production of new vaccines are: 1) different epitopes can be readily exchanged by "cutting and pasting" them into a recombinant vector that has been engineered to provide for maximal flexibility in vaccine design; 2) larger antigen sequences containing many target epitopes (i.e., whole proteins) or subunits (e.g., envelope proteins or receptor domains) can also be inserted if required; 3) the antigenic Figure 13 . IL-12, γ-IFN and ß-2 microglobulin knockout mouse study. γ-IFN knockout (n=6/group), IL-12 knockout (n=6/group) and β-2 microglobulin knockout (n=7/group) female mice were vaccinated subcutaneously with L-gD23-HD or control liposomes on day 0 and at week 8. All mice were primed with depoprovera on day -7 and day -1 prior to intravaginal challenge on week 9 with 10 LD 50 HSV2 determined for each strain by LD 50 dose studies in the intravaginal model. There was no significant difference between any of the immunized and the corresponding control groups. Symbol legend: L-gD23-HD γ-IFN group (-■-); LgD23-HD IL-12 group (-▲-); L-gD23-HD β-2 microglobulin group (-♦-); γ-IFN control group (-□-); IL-12 control group (-∆-) and; β-2 microglobulin control group (-◊-).
construct is produced by standard methods; 4) intricate, time consuming and, in the case of vaccines against biological weapons, potentially hazardous and expensive production methods associated with whole pathogen vaccines are eliminated; 5) the shelf life stability of the liposomes is likely to be much longer than that of microbial vaccines; 6) precise control over the processes used to manufacture VesiVax  vaccines is possible, resulting in a commercially viable approach to rapid vaccine development and large scale production and; 7) adverse side effects linked to the use of certain adjuvants, such as alum or associated with the use of intact agents, such as killed or attenuated viruses or bacteria, are minimized. Because of these advantages, the VesiVax  system should provide a new method for responding readily to the emergence of new pathogens. 
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